{"id":1903,"date":"2017-02-20T11:44:53","date_gmt":"2017-02-20T11:44:53","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1903"},"modified":"2025-05-19T10:47:32","modified_gmt":"2025-05-19T05:17:32","slug":"diminishing-pipeline-of-galectin-inhibitors","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors","title":{"rendered":"Diminishing pipeline of Galectin Inhibitors"},"content":{"rendered":"<p>Galectin belongs to the family of lectins that has the ability to bind to \u03b2-galactose, and binds to glycoproteins that are present on the extracellular as well as intracellular surface. Galectins have varied roles in many cellular functions like adhesion, migration, polarity, chemotaxis, proliferation, apoptosis and differentiation, with 15 mammalian galectins being identified till now. Out of all types of galectins, Galectin-1 and Galectin-3 plays an important role in progression of cancer and its metastasis.<\/p>\n<p>There are drugs being developed for the inhibition of Galectins- particularly Galectin-1 and Galectin-3- where chemically modified heparin derivatives like N-acetylated heparin derivatives act on Galectin-3 and inhibits its action in diseases like cancer and solid tumors. Currently, Galectin therapeutics is developing galectin inhibitors that are carbohydrate based drug compounds. Its drug candidate, GR-MD-02, is in its mid stage of development mainly for the treatment of fibrotic liver disease associated with fatty liver disease. Though galectins are becoming the major cause of various diseases like chronic kidney disease, hepatic fibrosis, inflammation, but there are very few companies that are in progress of developing galectin inhibitors.<\/p>\n<p>The pipeline for galectin inhibitors is decreasing rapidly due to very less success in studies being conducted. Earlier there were around 16 drugs that were in progress of development for various indications, but only some of them remained active. Though there are some companies like Galectin therapeutics, Bristol Myers Squibb, Glycomantra and Cancure who are in progress of developing inhibitors of Galectin, but mostly drugs like GCS 100, OTX008 which were earlier being developed got discontinued and inactive when the respective company failed to gain any progress in mid stage development. With current scenario of Galectin inhibitors, there are only few drugs in pipeline of galectin inhibitors that has potential of being marketed and developed further, leaving a great unmet need in terms of inhibiting this target for controlling many diseases.<\/p>\n<h6><em>Insight by:<br \/>\nNeha Chaudhary<br \/>\nAssociate Analyst<\/em><\/h6>\n<h6>DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating their decision-making. DelveInsight also serves as a knowledge partner for business strategy and market research. We provide comprehensive analytical reports across various therapeutic&nbsp;indications. DelveInsight has a database of 3000+ high-quality analytical <a href=\"https:\/\/www.delveinsight.com\/report-store.php\">reports<\/a>.<\/h6>\n","protected":false},"excerpt":{"rendered":"<p>Galectin belongs to the family of lectins that has the ability to bind to \u03b2-galactose, and binds to glycoproteins that are present on the extracellular as well as intracellular surface. Galectins have varied roles in many cellular functions like adhesion, migration, polarity, chemotaxis, proliferation, apoptosis and differentiation, with 15 mammalian galectins being identified till now. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1904,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[784,130,17456,735,634,783,17454,17455,17457,785],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-1903","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-bms","tag-bristol-myers-squibb","tag-cancure","tag-clinical-studies","tag-drug-development","tag-galectin-inhibitors","tag-galectin-therapeutics","tag-glycomantra","tag-mechanism-of-action-insight","tag-pipeline-insight","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Galectin Inhibitors and a weak pipeline | DelveInsight<\/title>\n<meta name=\"description\" content=\"Galectin belongs to the family of lectins that has the ability to bind to \u03b2-galactose, and binds to glycoproteins that are present on the extracellular\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Galectin Inhibitors and a weak pipeline | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"Galectin belongs to the family of lectins that has the ability to bind to \u03b2-galactose, and binds to glycoproteins that are present on the extracellular\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-20T11:44:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-19T05:17:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/galectin-inhibitor.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"550\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Galectin Inhibitors and a weak pipeline | DelveInsight","description":"Galectin belongs to the family of lectins that has the ability to bind to \u03b2-galactose, and binds to glycoproteins that are present on the extracellular","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors","og_locale":"en_US","og_type":"article","og_title":"Galectin Inhibitors and a weak pipeline | DelveInsight","og_description":"Galectin belongs to the family of lectins that has the ability to bind to \u03b2-galactose, and binds to glycoproteins that are present on the extracellular","og_url":"https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-02-20T11:44:53+00:00","article_modified_time":"2025-05-19T05:17:32+00:00","og_image":[{"width":550,"height":330,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/galectin-inhibitor.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors","url":"https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors","name":"Galectin Inhibitors and a weak pipeline | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/galectin-inhibitor.jpg","datePublished":"2017-02-20T11:44:53+00:00","dateModified":"2025-05-19T05:17:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Galectin belongs to the family of lectins that has the ability to bind to \u03b2-galactose, and binds to glycoproteins that are present on the extracellular","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/diminishing-pipeline-of-galectin-inhibitors#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/galectin-inhibitor.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/galectin-inhibitor.jpg","width":550,"height":330},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/galectin-inhibitor-300x180.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">BMS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancure<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Clinical Studies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">drug development<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Galectin Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Galectin Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Glycomantra<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Mechanism Of Action Insight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pipeline insight<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BMS<\/span>","<span class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/span>","<span class=\"advgb-post-tax-term\">Cancure<\/span>","<span class=\"advgb-post-tax-term\">Clinical Studies<\/span>","<span class=\"advgb-post-tax-term\">drug development<\/span>","<span class=\"advgb-post-tax-term\">Galectin Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">Galectin Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Glycomantra<\/span>","<span class=\"advgb-post-tax-term\">Mechanism Of Action Insight<\/span>","<span class=\"advgb-post-tax-term\">Pipeline insight<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Feb 20, 2017","modified":"Updated on May 19, 2025"},"absolute_dates_time":{"created":"Posted on Feb 20, 2017 11:44 am","modified":"Updated on May 19, 2025 10:47 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1903"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1903\/revisions"}],"predecessor-version":[{"id":32211,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1903\/revisions\/32211"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1904"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1903"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1903"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}